Mathurin Fumery
Prof Mathurin Fumery is an expert in Gastroenterology at Centre Hospitalier Universitaire Amiens-Picardie (France). As of October 2026, ScienceLeadR ranks Mathurin Fumery in the top 1% of experts worldwide for Crohn Disease, Inflammatory Bowel Diseases and Gastroenteritis. Mathurin Fumery has authored 641 publications, the most recent in 2026, and is an investigator in 52 clinical trials, 26 of them ongoing. SLR score: 2,803 (community average: 125). How the SLR is computed.
LeadR Profile
Gastroenterology
Subspecialties: Hepatology - Pharmacy - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2009 - 2026
Number : 641
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Chronic conditions associated with paediatric onset inflammatory bowel diseases: A population-based study. PMID 42872562 — inflammatory bowel diseases, obesity, diagnosis, gastrointestinal diseases, infections | J Pediatr Gastroenterol Nutr | 2026 | 0 |
| Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn's disease: Results of the ACCEPT-OBI study. PMID 42729518 — injections, crohn disease, maintenance, drug-related side effects and adverse reactions, inflammatory bowel diseases, therapeutics, infusions, intravenous | Ther Adv Gastroenterol | 2026 | 0 |
| Management of sigmoid diverticular abscess by surgeons and gastroenterologists: a French survey. PMID 42635713 — abscess, drainage, colon, sigmoid, diverticulitis, therapeutics, general surgery, gastroenterologists, surgeons | Updates Surg | 2026 | 0 |
| Perchlorate exposure and human health: Integrating biomonitoring evidence, thyroid mechanisms, and risk assessment. PMID 42546630 — risk assessment, thyroid gland, biological monitoring, research, environmental health, environment | Sci Total Environ | 2026 | 0 |
| Methotrexate for inflammatory bowel disease: the MICI-METHO multicenter retrospective cohort study. PMID 42484615 — safety, cohort studies, drug-related side effects and adverse reactions, inflammatory bowel diseases, therapeutics, methotrexate | J Crohns Colitis | 2026 | 0 |
Clinical Studies 52
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 15
Ongoing Clinical Trials
26 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy and Safety of JNJ 78934804 in Participants With Moderately to Severely Active Crohn s Disease 2026-525922-39-00 — safety, crohn disease | Phase 3 | Not yet recruiting | 2026 |
| Efficacy and Safety of JNJ 78934804 in Participants with Moderately to Severely Active Ulcerative Colitis 2026-525923-26-00 — colitis, safety, colitis, ulcerative | Phase 3 | Recruiting | 2026 |
| A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn s disease 2025-521037-86-00 — safety, crohn disease, maintenance, immune system diseases, immune system | Phase 3 | Recruiting | 2026 |
| Crohn s Head to Head Assessing Risankizumab Versus Guselkumab for One Year 2025-521590-13-00 — safety, crohn disease, therapeutics, head | Phase 3 | Recruiting | 2026 |
| A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative colitis 2025-521038-27-00 — colitis, safety, maintenance, immune system diseases, immune system, colitis, ulcerative | Phase 3 | Recruiting | 2026 |
LeadR Networks
Main global connection map